Lilly’s quarterly profit falls, but tops analyst expectations
Eli Lilly and Co. reported second-quarter profit that fell less than analysts had expected. The company raised its outlook for the rest of the year.
Health Care
Articles
Potential Alzheimer’s drug fails first of four key trials
Bapineuzumab is in a race with a similar product from Indianapolis-based Eli Lilly and Co. to become the first therapy to target a cause for Alzheimer’s, rather than just its symptoms.
Survey: Solo practices nearly gone
Only 1 percent of the jobs given to Texas-based Merritt Hawkins over the past year were for solo practitioners, the physician recruiting firm reported this month. That’s down from 22 percent of all searches in 2004.
Suburban hospitals charm patients
A little extra Medicare money will flow to suburban hospitals in the Indianapolis area, based on recent patient satisfaction scores. But hospitals in the core of Indianapolis—and hospitals that do significant amounts of teaching medical students—may take a hit.
Insurance company key to Franciscan-American Health partnership
Hospital system’s health insurance unit has IT infrastructure that will allow physicians to participate in Medicare’s shared savings program.
Westfield health IT firm sold for $473 million
MaxIT’s 1,300 employees, who provide information technology services to hospitals and physician practices, will join Virginia-based Science Applications International Corp.
IU Health makes prestigious Honor Roll list
For the first time, Indiana University Health has been named to U.S. News & World Report's "Best Hospitals Honor Roll," a distinction that goes to the top medical centers in the country.
WellPoint agrees to pay for 3 children to get gene test
WellPoint Inc. said it will pay for DNA testing for three children to see if they have an inherited heart disease their father suffers from that often strikes without warning, reversing an earlier decision to deny coverage.
Potential Lilly antipsychotic falls short in study
Eli Lilly and Co. said a potential treatment for acute schizophrenia failed in a late-stage study that compared patients taking the drug to those taking a placebo.
Competing Alzheimer’s treatments facing long odds
Johnson & Johnson, Pfizer Inc. and Elan Corp are racing Indianapolis-based Eli Lilly and Co. to market the first broadly available drug designed to target a cause of Alzheimer’s, rather than just its symptoms. Analysts say the potential drugs are long shots.
Zoeller goes after closed Allcare Dental chain
A chain of dental offices that abruptly closed multiple Indiana locations in December 2010 left patients without care, refunds or records, according to a complaint filed by the Office of the Indiana Attorney General.
Local providers join Medicare ACO program
Indiana University Health, as well as a partnership of Franciscan Alliance and American Health Network, have formed accountable care organizations that won the blessing of the federal Medicare Shared Savings program.
Lilly gets 6-month Cymbalta marketing extension
Eli Lilly and Co. said Friday that it has received an extra six months of marketing exclusivity on the antidepressant Cymbalta, its biggest selling drug. The extension could mean more than a billion dollars in sales for the Indianapolis drug maker.
Fairbanks leader Cross stepping down after impressive run
When Helene Cross arrived to lead Fairbanks Addiction Treatment Center in 2001, the alcohol and drug rehabilitation hospital was as sick financially as its patients were physically.
Doctors, hospitals follow only parts of Regenstrief’s IT prescription
The great results Regenstrief Institute has produced over the years in studies at Indianapolis’ Wishard Memorial Hospital have not held up when conducted in a wider variety of settings.
Bristol-Myers to buy former Lilly partner Amylin for $5.3B
Bristol-Myers Squibb Co. has agreed to pay $5.3 billion to acquire former Eli Lilly and Co. partner Amylin Pharmaceuticals Inc., a maker of diabetes therapies. The deal is valued at about $7 billion, which includes Amylin’s debt and a payment to Eli Lilly and Co. of about $1.7 billion.
Q&A
The U.S. Supreme Court’s ruling to uphold the Patient Protection & Affordable Care Act cleared a big cloud of uncertainty for employers, but with just 18 months before the most significant provisions of the law kick in, many questions remain. Three benefits consultants from Indianapolis-based Gregory & Appel Insurance—Bob Miller, Mike Miles and Karl Ahlrichs—sat down to discuss what the future looks like for employer health benefits.
High court health care decision good for some, not others
The Supreme Court's decision Thursday to uphold President Barack Obama's historic overhaul is expected to boost many players in the health care industry, but not every corner of the sector will benefit.
High court ruling opens Medicaid escape hatch for states
While upholding President Obama’s health care law, the U.S. Supreme Court may have created a way out for states that do not want to expand their Medicaid programs. Whether Indiana decides to opt out remains to be seen.
High court ruling could leave 290K Hoosiers uncovered
A decision by Indiana to leave its Medicaid program unchanged could leave as many as 290,000 Hoosier adults, who would have been newly eligible for Medicaid coverage, with no good options.